Table 1 Baseline charasteristics and medicatoins of the participants
From: Anti-inflammatory effects of empagliflozin in patients with type 2 diabetes and insulin resistance
Placebo (n = 51) | EMPA (n = 51) | P value | |
|---|---|---|---|
Age (years) | 58.1 ± 9.71 | 57.4 ± 12.3 | 0.778 |
Male/(female) | 41 (10) | 38 (13) | 0.636 |
Baseline medication | |||
Slfonylureas | 11 | 10 | 1 |
Metformin | 12 | 12 | 1 |
α-GI | 8 | 7 | 1 |
ARB | 16 | 17 | 0.915 |
CCB | 10 | 10 | 1 |
Statins | 17 | 16 | 1 |
Fibrates | 9 | 10 | 0.879 |